.avif)
.avif)
.avif)
Denali Therapeutics Email Format
Biotechnology Research
・
501-1,000 employees
・
South San Francisco, CA, USA
Denali Therapeutics is a biotechnology company developing biotherapeutics designed to cross the blood-brain barrier for neurodegenerative and lysosomal storage diseases.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
last@dnli.com
Company Overview
Industry
Biotechnology Research
Founded
2015
Headquarters
South San Francisco, CA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Key Executives
Ryan Watts (Chief Executive Officer), Alexander Schuth (Chief Operating and Financial Officer), Dana Andersen, Ph.D. (Chief Technical and Manufacturing Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Denali Therapeutics?
Denali Therapeutics uses the last@dnli.com format on denalitherapeutics.com, so Jane Smith would be smith@denalitherapeutics.com.
What is Denali Therapeutics' TransportVehicle platform designed to do?
Denali Therapeutics' TransportVehicle platform is a proprietary technology built to deliver large therapeutic molecules, including antibodies, enzymes, and oligonucleotides, across the blood-brain barrier after intravenous administration, enabling treatment of diseases in the central nervous system.
Who co-founded Denali Therapeutics and currently serves as its CEO?
Ryan Watts, Ph.D. co-founded Denali Therapeutics and serves as its CEO. He previously directed the Department of Neuroscience at Genentech, where he led the company's re-entry into neuroscience and worked on drug delivery across the blood-brain barrier.
Which rare disease is Denali Therapeutics' lead drug candidate tividenofusp alfa targeting?
Tividenofusp alfa, also known as DNL310, is Denali Therapeutics' lead drug candidate targeting Hunter syndrome, or MPS II, a rare and progressively debilitating genetic disorder. The FDA granted accelerated approval to tividenofusp alfa for neurologic Hunter syndrome in 2026.
How can I find and verify the right Denali Therapeutics contact for outreach?
With 575 employees based primarily in South San Francisco, Denali Therapeutics has a focused team across research, clinical, and operations functions. Tools like Clay can help you verify a specific contact's email or enrich a prospect list with accurate Denali Therapeutics employee details.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating